Infiniti Medlab Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.50 M
- Company Age 18 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.40 Cr
- Revenue Growth -19.05%
- Profit Growth -70.97%
- Ebitda -151.57%
- Net Worth -2.31%
- Total Assets -14.48%
About Infiniti Medlab
Infiniti Medlab Private Limited (IMPL) is a Private Limited Indian Non-Government Company incorporated in India on 11 September 2006 and has a history of 18 years and five months. Its registered office is in Delhi, India.
The Company is engaged in the Information Technology Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹1.40 Cr.
Himanshu Sachdeva, Rashi Sachdeva, and Sweena Sachdeva serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U33125DL2006PTC153491
- Company No.
153491
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Sep 2006
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Infiniti Medlab?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Himanshu Sachdeva  | Director | 11-Sep-2006 | Current |
| Rashi Sachdeva | Director | 26-Dec-2024 | Current |
| Sweena Sachdeva | Director | 11-Sep-2006 | Current |
Financial Performance of Infiniti Medlab.
Infiniti Medlab Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 19.05% decrease. The company also saw a substantial fall in profitability, with a 70.97% decrease in profit. The company's net worth dipped by a decrease of 2.31%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Infiniti Medlab?
In 2019, Infiniti Medlab had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹14.00 M
₹0
Charges Breakdown by Lending Institutions
- Canara Bank : 1.20 Cr
- Others : 0.20 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 08 Oct 2024 | Others | ₹2.00 M | Open |
| 15 Jan 2007 | Canara Bank | ₹2.00 M | Open |
| 15 Jan 2007 | Canara Bank | ₹1.00 Cr | Open |
How Many Employees Work at Infiniti Medlab?
Unlock and access historical data on people associated with Infiniti Medlab, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Infiniti Medlab, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Infiniti Medlab's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
